A 70-year-old with HFrEF (EF 30%) is stable. Which therapy class provides mortality/hospitalization benefit and is now core therapy across EF ranges?...

Question

A 70-year-old with HFrEF (EF 30%) is stable. Which therapy class provides mortality/hospitalization benefit and is now core therapy across EF ranges?

Accepted Answer

SGLT2 inhibitors

Answer

DPP-4 inhibitors

Answer

Thiazolidinediones

Answer

Ivabradine as monotherapy

Answer

Digoxin as monotherapy

us-abim MCQ (SBA): Heart Failure (pharmacotherapy)